breast cancer

Breast cancer trials cover the full spectrum of disease β€” from ductal carcinoma in situ (DCIS) to metastatic HER2-positive and triple-negative subtypes β€” with an emphasis on biomarker-driven patient selection. Neoadjuvant approaches that shrink tumors before surgery and adjuvant therapies that reduce recurrence risk are active areas of investigation, alongside novel agents targeting PI3K, CDK4/6, and PARP pathways.

Current trials test CDK4/6 inhibitors, HER2-targeted combinations, PARP inhibitors for BRCA1/2 carriers, immunotherapy in triple-negative breast cancer, and endocrine therapies for hormone-receptor-positive disease. Trials also study de-escalation strategies to reduce overtreatment in low-risk early-stage patients.

Eligibility often depends on hormone receptor (HR) and HER2 status, BRCA mutation status, and prior treatment history.

Disease Burden & Epidemiology

Breast cancer is the most commonly diagnosed cancer in women worldwide and the second most common cancer overall. In 2022, approximately 2.3 million women were diagnosed globally, accounting for 11.7% of all cancer cases. In the United States, the American Cancer Society projects roughly 310,000 new cases of invasive breast cancer and 42,000 deaths annually. The lifetime risk for American women is approximately 1 in 8 (12.9%). Incidence rates have risen modestly over recent decades, largely attributed to increased mammographic screening and changing reproductive patterns including delayed first pregnancy and reduced breastfeeding duration. Mortality rates, however, have declined by 43% since 1989 — a direct result of early detection programs and improved systemic therapies validated through randomized clinical trials. Triple-negative breast cancer (TNBC), which lacks hormone receptors and HER2 amplification, carries the poorest prognosis and has historically had limited targeted treatment options, making it a primary focus of current clinical research. BRCA1 and BRCA2 germline mutations, found in 5–10% of cases, substantially elevate lifetime risk and qualify carriers for targeted prevention and treatment trials.

Key Research Trends & Landmark Studies

The monarchE trial established adjuvant abemaciclib (CDK4/6 inhibitor) as standard care for high-risk hormone-receptor-positive early breast cancer, representing the first CDK4/6 inhibitor approval in the curative setting. The OlympiA trial demonstrated that adjuvant olaparib (PARP inhibitor) reduces distant recurrence in BRCA1/2-mutated early breast cancer, establishing germline testing as mandatory for high-risk patients. DESTINY-Breast03 compared trastuzumab deruxtecan (T-DXd) versus T-DM1 in HER2-positive metastatic disease, showing a near-doubling of progression-free survival and earning a breakthrough approval. The KEYNOTE-522 trial established pembrolizumab plus chemotherapy as standard neoadjuvant therapy for high-risk TNBC, with pathological complete response serving as a primary endpoint. Currently enrolling trials include multiple neoadjuvant de-escalation studies (DECRESCENDO, EXPERT) asking whether patients achieving pCR can safely omit adjuvant chemotherapy, and first-in-human studies of antibody-drug conjugates targeting novel antigens including TROP-2, HER3, and B7-H4.

Patient Guide: How to Find & Join a Trial

Women diagnosed with breast cancer at any stage should ask their oncologist at initial diagnosis whether a clinical trial is appropriate β€” not only at relapse. Comprehensive breast cancer centers affiliated with major academic hospitals typically have the most robust trial portfolios, including access to pre-approval agents through expanded access programs. Before your appointment, request your complete pathology report including receptor status (ER, PR, HER2 by IHC and FISH), Ki-67 index, and grade β€” these determine eligibility for most trials. If you have a first-degree relative with breast or ovarian cancer, request germline BRCA1/2 and panel testing, as mutation status unlocks PARP inhibitor trials. For metastatic disease, tumor biopsy for next-generation sequencing (NGS) at diagnosis is increasingly recommended to identify actionable alterations including PIK3CA, BRCA somatic mutations, and NTRK fusions that match specific trial protocols.

Frequently Asked Questions — breast cancer Clinical Trials

Related Conditions